STE STERIS plc

NYSE Orthopedic, Prosthetic & Surgical Appliances & Supplies L2 CIK: 0001757898
AI RATING
BUY
78% Confidence

Investment Thesis

STERIS demonstrates exceptional financial health with fortress-like balance sheet (0.27x debt/equity, 2.48x current ratio) and robust free cash flow generation ($727.2M annually). However, net income declined 0.2% YoY despite 6.2% revenue growth, signaling margin compression that requires monitoring despite strong 18.1% operating margins.

Strengths

  • + Exceptional liquidity and conservative leverage with 2.48x current ratio, 1.75x quick ratio, and 0.27x debt/equity
  • + Outstanding debt service capacity with 25.8x interest coverage ratio and $727.2M annual free cash flow
  • + Healthy profitability with 44.4% gross margin and 18.1% operating margin demonstrating operational efficiency
  • + Consistent 6.2% YoY revenue growth in stable, defensive healthcare supplies sector with strong pricing power
  • + Strong free cash flow margin of 16.7% with sustainable capital expenditure at 27.9% of operating cash flow

Risks

  • ! Net income declined 0.2% YoY despite revenue growth, indicating margin compression and potential operating headwinds
  • ! Moderate capital efficiency with ROE of 7.9% and ROA of 5.3% suggesting suboptimal asset utilization
  • ! Limited insider activity (1 Form 4 filing in 90 days) may indicate low management conviction in current valuation
  • ! Exposure to healthcare sector regulatory risks, pricing pressures, and potential reimbursement changes
  • ! EPS growth of 62.7% appears driven by share buybacks rather than organic earnings growth, raising sustainability questions

Key Metrics to Watch

Financial Metrics

Revenue
4.3B
Net Income
562.1M
EPS (Diluted)
$5.69
Free Cash Flow
727.2M
Total Assets
10.6B
Cash
423.7M

Profitability Ratios

Gross Margin 44.4%
Operating Margin 18.1%
Net Margin 12.9%
ROE 7.9%
ROA 5.3%
FCF Margin 16.7%

Balance Sheet & Liquidity

Current Ratio
2.48x
Quick Ratio
1.75x
Debt/Equity
0.27x
Debt/Assets
32.3%
Interest Coverage
25.84x
Long-term Debt
1.9B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-16T16:57:23.741830 | Data as of: 2025-12-31 | Powered by Claude AI